Sandoz reports data from Phase I/III trial of denosumab for osteoporosis

Novartis subsidiary Sandoz has reported positive data from the integrated Phase I/III ROSALIA clinical trial of its proposed biosimilar denosumab to treat osteoporosis.

The trial enrolled 527 postmenopausal women with osteoporosis.